[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-artery-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-artery-disease":642},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,476,0,25,[9,49,74,105,133,158,182,217,236,258,281,301,324,347,366,387,405,429,461,478,519,542,576,599,619],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053354",false,"NCT07000045","Intravascular Lithotripsy With or Without Rotational Atherectomy for Coronary Calcified Nodule Treatment","Coronary Calcified Nodule Management With Rotational Atherectomy Plus Shockwave Intravascular Lithotripsy vs. Intravascular Lithotripsy Alone: A Prospective, Randomized Trial (NODULE-SHOCK)","NODULE-SHOCK","Inclusion Criteria\n\n* Age ≥18 years who signed written informed consent\n* Presence of a clinical indication for coronary intervention\n* Patients undergoing PCI for a de novo calcified lesion with planned drug-eluting stent (DES) implantation\n* Native coronary artery with significant stenosis defined as:\n* ≥70% and \\\u003C100% stenosis on angiography, or\n* 50-70% stenosis with evidence of ischemia (positive stress test, FFR ≤ 0.8, or OCT minimal lumen area (MLA) ≤ 4.0 mm2)\n* Reference vessel diameter: ≥2.5 mm to ≤ 4.0 mm\n* Lesion length: ≥5mm\n* Moderate to severe calcification of the target lesion confirmed by angiography\n* Thrombolysis in Myocardial Infarction (TIMI) flow grade 3 at baseline\n\nExclusion Criteria\n\n* Cardiogenic shock at the time of procedure\n* Primary PCI for ST-segment elevation myocardial infarction (STEMI)\n* Pregnant, nursing, or childbearing potential without adequate contraception\n* Known allergy or contraindication to DAPT (aspirin, clopidogrel, prasugrel, ticagrelor)\n* Planned surgery within 6 months unless DAPT can be maintained\n* Life expectancy \\\u003C12 months due to a serious medical illness (e.g., advanced cancer, end-stage heart failure)\n* Severe kidney dysfunction (CrCl \\\u003C30 mL\u002Fmin) without dialysis\n* Concurrent participation in another investigational study\n* Referral for coronary artery bypass grafting (CABG) after a heart team discussion\n* Angiographic evidence of thrombus at the target lesion\n* Angiographic evidence of significant dissection at the treatment site prior to intervention\n* Lesion with a previously placed stent within 10mm (visual estimate)\n* Last remaining vessel with severely compromised left ventricular function (LVEF \\\u003C30%)\n* Target lesion within a saphenous vein graft (SVG)","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","The NODULE-SHOCK trial is a prospective, investigator-initiated, single-center, randomized controlled trial designed to compare the efficacy of intravascular lithotripsy (IVL) with or without rotational atherectomy (RA) in patients with coronary calcified nodules (Cohort A), and operator-determined vs maximum IVL pulses in patients with non-nodular severe coronary calcium (Cohort B).",[27,28],"Coronary Artery Disease","Coronary Calcification",[30,31,32,33,34,35],"Coronary calcification","Calcified nodule","Intravascular lithotripsy","Rotational atherectomy","Optical coherence tomography","Percutaneous coronary intervention","RECRUITING","2026-07-10",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":40},"2025-10-06",{"date":44,"type":21},"2027-12-31",{"name":46,"class":47},"Annapoorna Kini","OTHER",1,{"id":50,"slug":4,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":48},"100053907","NCT07355192","Hybrid Group Singing","Group Singing (Hybrid Format) or Solo Singing in Older Adults With Coronary Artery Disease: A Feasibility Study","Inclusion Criteria:\n\n* history of coronary artery disease (defined as having at least 1 of the following: myocardial infarction, coronary stent, PCI, CABG, coronary stenosis at least 50%, or coronary artery calcification score at least 300 Agatston units)\n\nExclusion Criteria:\n\n* Parkinson's disease or tremor\n* upper arm fistula\n* fingernail onychomycosis\n* pregnancy\n* current tobacco use\n* current illicit drug use\n* current excessive alcohol use (defined as more than 14 drinks\u002Fweek for women, more than 28 drinks\u002Fweek for men)\n* unstable CAD (active symptoms of chest discomfort)\n* supplemental oxygen use\n* more than mild cognitive impairment (as documented in the medical record by patient's treatment teams)\n* inability to follow study procedures\n* non-English speaking","55 Years","89 Years",{"count":58,"type":21},32,[24],"The overall objective of the planned future clinical trial is to test the investigator's central hypothesis that habitual singing over several weeks, similar to habitual exercise, will lead to sustained and favorable vascular adaptation, thereby lowering cardiovascular disease (CVD) risk. The overall objective of this study is to refine and protocolize the singing interventions and test the feasibility of the future trial design. The investigative team has previously studied solo singing. Collective singing, as in a choir or small group, is associated with a positive sense of social inclusion, well-being, and improved mood, including in older adults.",[27,62],"Elderly",[64,65],"group singing","individual singing","2026-07-09",{"date":39,"type":40},{"date":69,"type":40},"2026-05-11",{"date":71,"type":21},"2028-02",{"name":73,"class":47},"Medical College of Wisconsin",{"id":75,"slug":4,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":48},"100054302","NCT07699679","Photobiomodulation in Coronary Artery Bypass Grafting With No-Touch vs Conventional Saphenous Vein Harvesting.","Impact of Photobiomodulation in Coronary Artery Bypass Surgery: Comparison Between No-Touch and Conventional Saphenous Vein Harvesting Techniques on Clinical Outcomes, Functional Capacity, and Wound Healing: A Randomized Clinical Trial","PHOTON","Inclusion Criteria:\n\n* Patients diagnosed with coronary artery disease scheduled to undergo elective coronary artery bypass grafting (CABG)\n* Use of the saphenous vein as a graft for myocardial revascularization\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Emergency coronary artery bypass surgery\n* Previous surgery in the lower limb that prevents saphenous vein harvesting\n* Active infection at the surgical site or lower limb\n* Severe peripheral arterial disease in the lower limbs\n* Hemodynamic instability preventing study protocol procedures\n* Participation in another interventional clinical trial that may interfere with the outcomes of this study\n* Patients unable to perform postoperative functional capacity assessments\n* Individuals with highly pigmented skin or sensibility that may alter light absorption and penetration of the photobiomodulation therapy.","75 Years",{"count":83,"type":21},292,[24],"This randomized, double-blind clinical trial aims to evaluate the impact of photobiomodulation therapy on postoperative outcomes in patients undergoing coronary artery bypass grafting (CABG). The study will compare two techniques for saphenous vein graft harvesting: the conventional technique and the no-touch technique. Participants will be randomly allocated into four groups: conventional harvesting with placebo, conventional harvesting with photobiomodulation, no-touch harvesting with placebo, and no-touch harvesting with photobiomodulation. The primary objective is to evaluate the effects of photobiomodulation on wound healing and postoperative complications related to the saphenous vein harvesting site. Secondary outcomes include clinical outcomes and functional capacity after surgery. The results may contribute to improving postoperative recovery and optimizing surgical strategies in patients undergoing myocardial revascularization.",[27,87,88],"Coronary Artery Bypass Graft (CABG)","Surgical Wound Healing",[90,91,92,93,94,95],"Photobiomodulation","Low-Level Laser Therapy","Coronary Artery Bypass Grafting","Saphenous Vein Harvesting","No-Touch Technique","Wound Healing","NOT_YET_RECRUITING","2026-07-08",{"date":39,"type":40},{"date":100,"type":21},"2026-08",{"date":102,"type":21},"2028-03",{"name":104,"class":47},"Federal University of São Paulo",{"id":106,"slug":4,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":119,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":48},"100585575","NCT06904144","Health Coaching for Patients With Cardiovascular Disease","Health Coaching for Patients With Cardiovascular Disease: A Mixed-Methods Evaluation of the Impact on Patient Outcomes and Provider Satisfaction and Acceptability","Inclusion Criteria:\n\n* 18 years of age or older\n* diagnosis of coronary artery disease resulting in myocardial infarction and\u002For congestive heart failure\n* physical condition effectively managed by routine healthcare and not requiring urgent medical attention\n* ability to communicate in English\n* access to a working phone or computer and ability to communicate via phone or computer.\n\nExclusion Criteria:\n\n* Patients who have had chest coronary artery bypass surgery\n* Documented cognitive and\u002For major psychiatric disorders, including dementia, Alzheimer's, depression or anxiety uncontrolled by anxiolytic, anti-psychotic, and\u002For anti-depressants and\u002For PHQ-9 score 15-27 and GAD-7 score \\>15\n* current alcohol or drug dependency\n* resident of extended care\u002Fskilled facility\n* prisoners or ward of state.",{"count":112,"type":21},70,[24],"For patients discharged with a diagnosis of cardiovascular disease coronary artery disease resulting in myocardial infarction and\u002For congestive heart failure, this study will evaluate if the addition of 12 virtual health coaching sessions over the course of 16 weeks will improve physiological, psychological, and social health outcomes, prove acceptable and satisfactory for these patients with CVD, decrease CVD-related questions and concerns sent to the provider via MyChart, and reduce hospital readmission rates over a 90-day period as compared to patients discharged with the same diagnosis who receive standard post-discharge care. The study will also evaluate the perceptions of physician and advanced practice providers related to the health coach as part of the interprofessional team and the amount of time spent addressing CVD-related patient questions and concerns via MyChart messages.",[116,117,27,118],"Congestive Heart Failure Treated","Myocardial Infarction (MI)","Congestive Heart Failure Chronic",[120,121,122,123],"health coaching","coronary artery disease","congestive heart failure","myocardial infarction","2026-06-30",{"date":126,"type":40},"2026-07-01",{"date":128,"type":21},"2026-10-01",{"date":130,"type":21},"2028-10-01",{"name":132,"class":47},"Ohio State University",{"id":134,"slug":4,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":140,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":48},"100147099","NCT01186133","Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice","Evaluation of Effectiveness and Safety of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice","IRIS-DES","Inclusion Criteria:\n\n* coronary disease amenable to percutaneous coronary intervention (PCI)\n* no clinical and lesion limitations\n\nExclusion Criteria:\n\n* patients with a mixture of several DES\n* terminal illness with life expectancy less than 1 year\n* patients with cardiogenic shock","19 Years",{"count":142,"type":21},50000,"OBSERVATIONAL","The objective of this study is to evaluate effectiveness and safety of the new drug-eluting stent (DES), as compared with the first-,second-,third-, and fourth-generation DES, in the \"real world\" daily practice.",[27,146],"Percutaneous Transluminal Coronary Angioplasty",[148,149],"coronary disease","drug eluting stent","2026-06-26",{"date":124,"type":40},{"date":153,"type":4},"2009-01",{"date":155,"type":21},"2030-12",{"name":157,"class":47},"Seung-Jung Park",{"id":159,"slug":4,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":140,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":181},"100396548","NCT04443530","Evaluation of Effectiveness and Safety of Ultimaster™ Tansei™ Stent and\u002For Ultimaster Nagomi™ Stent in Routine Clinical Practice","Evaluation of Effectiveness and Safety of Ultimaster™ Tansei™ Stent and\u002For Ultimaster Nagomi™ Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study","IRIS Tansei","Inclusion Criteria:\n\n1. Patients ≥ 19 years old\n2. Patients receiving Ultimaster™ Tansei™ stent and\u002For Ultimaster Nagomi™ stents.\n3. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthics Committee of the respective clinical site.\n\nExclusion Criteria:\n\n1. Patients with a mixture of other drug-eluting stents (DESs)\n2. Terminal illness with life-expectancy ≤1 year.\n3. Patients with cardiogenic shock",{"count":166,"type":21},2000,"This study is to evaluate the effectiveness and safety of Ultimaster Tansei stent and\u002For Ultimaster Nagomi stent in the \"real-world\" daily practice.",[27],[170,171,172],"Tansei","Ultimaster","Ultimaster Tansei","2026-06-24",{"date":150,"type":40},{"date":176,"type":40},"2020-09-17",{"date":178,"type":21},"2032-12-31",{"name":180,"class":47},"Duk-Woo Park, MD",11,{"id":183,"slug":4,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":140,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":191,"briefSummary":193,"conditions":194,"keywords":198,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":216},"100394478","NCT04416581","Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy","A Multi-centre, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Phase 4 Efficacy and Safety Study of P-CAB (Tegoprazan 50 mg Once Daily) Compared With PPI (Rabeprazole 20 mg Once Daily) to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease","PROTECT-HBR","Inclusion Criteria:\n\n1. Patients 19 years of age or older with known cardiac and vascular disease who are receiving chronic use of antithrombotic drugs (either antiplatelets, oral anticoagulant (OAC), and its combinations). Specific clinical conditions that may confer a need for long-term antithrombotic therapy may include documented coronary artery disease (stable or unstable angina, acute coronary syndrome, a history of myocardial infarction, or any coronary revascularization), documented cerebrovascular disease (stroke or transient ischemic attack), known peripheral arterial disease or a history of peripheral arterial revascularization, atrial fibrillation, or valvular heart disease requiring interventions (transcatheter aortic valve replacement or transcatheter mitral-valve repair). Concomitant use of a proton pump inhibitor is strongly recommended in patients receiving aspirin monotherapy, DAPT (dual antiplatelet therapy; aspirin plus any P2Y12 inhibitors), DAT (dual antithrombotic therapy; antiplatelet drug plus OAC), TAT (triple antithrombotic therapy; DAPT plus OAC), or OAC monotherapy (warfarin or direct oral anticoagulants) who are at high risk of GI bleeding in order to reduce the risk of gastric bleed or GI events. Based on clinical guidelines, the use of P2Y12 inhibitor monotherapy (i.e. clopidogrel, ticagrelor, or prasugrel) is not considered in trial enrollment.\n2. On the basis of clinical guidelines and expert consensus documents, we defined a study population with an increased risk of gastrointestinal bleeding if they had a least 1 or more criteria of the following characteristics. Eligible patients for randomization must meet at least 1 characteristic of these criteria:\n\n   \\*Definition of patients who are at high risk of gastrointestinal bleeding\n   1. Age ≥65 years\n   2. Concomitant use of OAC and any antiplatelet therapy (mono or DAPT) (i.e., DAT or TAT)\n   3. Long-term use of oral NSAIDs (non-steroidal anti-inflammatory drugs) or steroids or high-dose NSAID therapy even during a relatively short-term period.\n   4. History of prior GI bleeding events at any time\n   5. History of a previously complicated ulcer\n   6. History of peptic ulcer disease or a previously uncomplicated ulcer\n   7. Documented Helicobacter pylori infection\n3. Patients who voluntarily participated in the written agreement\n\nExclusion Criteria:\n\n1. Active bleeding at the time of inclusion or a history of hereditary or acquired hemostatic disorder\n2. Any clinical contraindication to using of antithrombotic therapies (antiplatelet agents or OAC)\n3. Concurrent use of PPI or P-CAB within 4 weeks before randomization\n4. Hemodynamically unstable conditions at the time of inclusion: cardiogenic shock at the time of randomization, refractory ventricular arrhythmias, or congestive heart failure (New York Heart Association class IV).\n5. Baseline severe anemia (Hgb \\\u003C8 g\u002Fdl at baseline) or transfusion within 4 weeks before randomization\n6. Baseline severe thrombocytopenia (platelet count \\\u003C50,000\u002Fmm3)\n7. Renal failure dependent on dialysis or severe renal insufficiency (creatinine clearance \\\u003C15 ml\u002Fmin)\n8. Severe chronic liver disease (defined as variceal haemorrhage, ascites, hepatic encephalopathy, or jaundice)\n9. Hypersensitivity or contraindication to PPI, P-CAB, any of the product components, or substituted benzimidazoles\n10. Use of clarithromycin and hypersensitivity to macrolide antibiotics for Helicobacter pylori eradication\n11. Concomitant use of clarithromycin with terfenadine, cisapride, astemizole, or pimozide for Helicobacter pylori eradication\n12. Systemic treatment with strong CYP 3A4 and p-glycoprotein (P-GP) inhibitors (e.g., systemic azole antimycotics, such as ketoconazole, and human immunodeficiency virus \\[HIV\\]-protease inhibitors, such as ritonavir)\n13. Patients who take atazanavir, nelfinavir, or rilpivirine-containing products (see Drug-Drug interaction section)\n14. Clinically significant laboratory abnormality at screening (estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin or elevated liver enzyme \\[AST, ALT, ALP, total bilirubin\\] \\> 3 times upper normal limit \\[UNL\\] or any other condition that, in the opinion of the Investigator, precludes participation in the study\n15. Any known or suspected malignancy\n16. Patients with non-cardiac co-morbidities with a life expectancy of less than 12 months\n17. Patients with active treatment for H-pylori infection\n18. Women who are pregnant or breastfeeding or female subjects, premenopausal who are not surgically sterile, or, if sexually active not practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and, for those of childbearing potential, who have a positive pregnancy test at screening\n19. Participation in another clinical study within 12 months. However, where at least one or more conditions are satisfied, it could be an exception according to an investigator's discretion;\n\n    1. Participated in the observational study expected no effect on the safety and\u002For effectiveness evaluation of this trial\n    2. Screening failed before any interventional factor is involved\n    3. Participated in academic trials like strategic or medical device comparison studies conducted under standard therapy provided that there is no additional risk or a specific procedure to a subject and no interference between this trial and other studies",{"count":190,"type":21},3320,[192],"PHASE4","The primary aim of this study is to evaluate the efficacy and safety of novel P-CAB (tegoprazan 50 mg once daily) as compared with standard PPI (rabeprazole 20 mg once daily) for protection of GI events in patients with known cardiac and vascular disease receiving chronic use of antithrombotic drugs (either antiplatelets, OAC, and its combinations) who are at high GI bleeding risk. The primary hypothesis is that P-CAB (experimental arm) would non-inferior to PPI (standard arm) with respect to the rate of the primary composite end point of GI events at 12 months after randomization.",[27,195,196,197],"Percutaneous Coronary Intervention","Acute Coronary Syndrome","Myocardial Infarction",[199,200,201,202,203,204,205,206,207,208,209],"gastroduodenal ulcer","gastrointestinal hemorrhage","peptic ulcer","acute coronary syndrome","coronary artery stent placement","antiplatelet","anticoagulant therapy","PPI","P-CAB","Proton-pump inhibitors","Potassium-Competitive Acid Blockers",{"date":150,"type":40},{"date":212,"type":40},"2021-05-12",{"date":214,"type":21},"2028-02-28",{"name":180,"class":47},45,{"id":218,"slug":4,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":4},"100644890","NCT07675005","The Prospective, Multicenter, Randomized Controlled Trial of the VentriCure Interventional Left Ventricular Assist System","The Prospective, Multicenter, Randomized Controlled Clinical Trials Comparing the VentriCure Left Ventricular Assist System With ECMO for Supporting High-risk PCI Procedures","Inclusion Criteria:\n\n1. Patient age ≥18 years old;\n2. As assessed by the cardiac team the patient needs coronary revascularization, but CABG (Coronary Artery Bypass Grafting) is of high risk, or the patient refuses to undergo CABG;\n3. The patient is meeting one of the following:\n\n(1) Coronary Artery Disease and left ventricular ejection fraction ≤35%; (2) Coronary Artery Disease and left ventricular ejection fraction ≤40% and severe heart failure; 4. PCI was required for imaging diagnosis; 5. Patient willing and able to comply with protocol requirements and accept clinical follow-up; able to understand study purpose and sign informed consent.\n\nExclusion Criteria:\n\n1. Cardiac arrest within 24 hours;\n2. The implantation of an interventional left ventricular assist system was either contraindicated or not feasible;\n3. ST-segment elevation myocardial infarction (STEMI) within 24 hours;\n4. Chronic Kidney Disease;\n5. Severe right heart failure or severe tricuspid regurgitation;\n6. Presence of abnormal coagulation parameters (platelet count ≤75,000\u002Fmm\\^3, INR≥2.0, or fibrinogen ≤1.50g\u002FL);\n7. Moderate or higher anemia;\n8. History of stroke or transient ischemic attack (TIA) within one month;\n9. Allergy or intolerance to anticoagulants or contrast agent;\n10. Active internal bleeding within a month;\n11. Presence of uncontrolled active infection;\n12. Pregnant or lactating women;\n13. Patients are participating in other clinical trials;\n14. Other circumstances that are determined by the investigator to be unsuitable for the study.",{"count":224,"type":21},220,[24],"This study aims to evaluate the safety and effectiveness of the VentriCure interventional left ventricular assist system for short-term ventricular support during high-risk percutaneous coronary intervention (HRPCI) in non-emergent, hemodynamically stable coronary artery disease patients via a prospective, multi-center, randomized controlled clinical trial.",[27],"2026-06-23",{"date":124,"type":40},{"date":231,"type":21},"2026-07-30",{"date":233,"type":21},"2028-12-30",{"name":235,"class":47},"Life Shield Medical Technology Co., LTD",{"id":237,"slug":4,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":140,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":245,"conditions":246,"keywords":247,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":251,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":257},"100585909","NCT06908499","The DECISION-CTO Extended 10 Y Follow-up","Ten-Year Outcomes of Randomized Comparison of Drug-eluting Stent Implantation Versus Optimal Medical Treatment in Patient With Chronic Total Occlusion: DECISION-CTO Trial","DecisionCTO10Y","Inclusion Criteria:\n\n1. Clinical 1) Patients with angina or silent ischemia and documented ischemia 2) Patients who are eligible for intracoronary stenting 3) Age \\>18 years\n2. Angiographic 1) De novo lesion Chronic Total Occlusion (CTO) 2) Reference vessel size ≥ 2.5 mm by visual estimation 3) At least one CTO lesions located in proximal or mid epicardial coronary artery.\n\n   (If the patient has two CTO lesions, one CTO lesion should be located in proximal or mid epicardial coronary artery)\n3. CTO definition: TIMI (Thrombolysis in Myocardial Infarction) flow 0 or 1 with estimated duration over 3 months\n\n   * The duration of the occlusion was determined by the interval from the last episode of acute coronary syndrome, or\n   * In patients without a history of acute coronary syndrome, from the first episode of effort angina consistent with the location of the occlusion\n\n     1. Angiographically defined total occlusion over 3 months\n     2. If no definite symptom with total occlusion, two experienced operators decide CTO in consideration of angiographical morphology (degree of calcification, bridging collaterals, non-tapered stump, angiographic filling from collaterals)\n\nExclusion Criteria:\n\n1. History of bleeding diathesis or coagulopathy\n2. Pregnant state\n3. Three vessel CTOs\n4. Known hypersensitivity or contra-indication to contrast agent and heparin\n5. ST-elevation acute myocardial infarction requiring primary stenting\n6. Culprit total occlusion presented with acute coronary syndrome suggesting acute or recent occlusion\n7. Characteristics of lesion 1) Left main disease 2) In-stent restenosis 3) Graft vessels 4) Distal epicardial coronary artery CTO lesions 5) Two vessel proximal segment CTOs\n8. Hematological disease (Neutropenia \\\u003C3000\u002Fmm3, Thrombocytopenia \\\u003C100,000\u002Fmm3)\n9. Hepatic dysfunction, liver enzyme (ALT and AST) elevation ≥ 3 times normal\n10. Renal dysfunction, creatinine ≥ 2.0mg\u002FdL\n11. Contraindication to aspirin, clopidogrel or other commercial antiplatelet agent\n12. Left ventricular ejection fraction \\\u003C30%\n13. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.\n14. Non-cardiac co-morbid conditions are present with limited life expectancy or that may result in protocol non-compliance (per site investigator's medical judgment).",{"count":244,"type":21},840,"The goal of this clinical trial is to compare long term efficacy of drug-eluting stent implantation compare to optimal medical treatment in patient with chronic total occlusion in a very long-term follow-up (minimum 10 years) period.",[27],[248,249,250],"Chronic Total Occlusion","Drug-eluting Stent Implantation","Optimal Medical Treatment",{"date":173,"type":40},{"date":253,"type":40},"2026-04-01",{"date":255,"type":21},"2026-12-31",{"name":157,"class":47},19,{"id":259,"slug":4,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":264,"targetDuration":266,"studyType":143,"phases":4,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":274,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":257},"100540816","NCT06321757","PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients","PARIS","Inclusion Criteria:\n\nPatients with:\n\n* PCI with DCB on native arteries with diameters \\\u003C 3 mm.\n* Indication for PCI in acute coronary syndrome or chronic coronary syndrome or silent angina with an indication for PCI.\n\nsyndrome or silent angina with an indication for PCI.\n\n* If previous lesion preparation was required after which angiographic residual lesion should not exist with diameter stenosis \\> 30% or flow-limiting coronary dissections.\n* All antithrombotic therapies administered prior to the procedure are accepted. Still, they can be changed after the procedure.\n* Capacity to understand and sign the written informed consent.\n* If the patient has a high-bleeding risk defined by 1) PRECISE-DAPT SCORE ≥ 25 or 2) an indication for concomitant oral anticoagulation he can be included in the high- bleeding risk substudy as long as he does not meet the specific exclusion criteria.\n\nExclusion Criteria:\n\nPatients with:\n\n* Concomitant lesions on vessels \\> 3 mm in diameter in the same coronary territory.\n* PCI on in-stent restenoses.\n* PCI on culprit lesions of acute coronary syndrome with ST segment elevation.\n* Patients with an indication for PCI on additional non-culprit lesions of acute coronary syndrome with ST segment elevation may be included in the study, if only non-culprit lesions are considered for the study.\n* Life expectancy \\\u003C12 months\n* Pregnancy.\n* Participation in clinicaltrials.\n* Inability to give the written informed consent.\n* Specific exclusion criteria for the high-bleeding risk patient subgroup:\n* Past medical history of stent thrombosis.\n* Indication for dual antiplatelet therapy for a different reason.",{"count":265,"type":21},501,"5 Years","Post-market, prospective, observational, multicenter, non-intervention study, to demonstrate the effectiveness of drug-coated ballon (DCB)therapy in real-world patients with small native vessel coronary artery disease, and to demonstrate the safety of short dual antiplatelet therapy (7 days) in high-bleeding risk patients with native small vessel coronary artery disease treated with DCB therapy. A percutaneous coronary intervention (PCI) with DCB will be performed in patients with native vessel coronary artery disease based on the criterion of the treating physician.",[27],[270,271,272,273],"drug-coated balloon","paclitaxel","small native vessel coronary artery disease","coronary stenoses",{"date":173,"type":40},{"date":276,"type":40},"2024-02-26",{"date":278,"type":21},"2026-12-30",{"name":280,"class":47},"Fundación EPIC",{"id":282,"slug":4,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":17,"minAge":140,"maxAge":4,"enrollmentInfo":288,"targetDuration":266,"studyType":143,"phases":4,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":300,"locationsCount":181},"100529743","NCT06177743","IRIS-Coroflex NEO Cohort","Evaluation of Effectiveness and Safety of Coroflex ISAR NEO Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study","IRIS Coroflex","Inclusion Criteria:\n\n1. Patients ≥ 19 years old\n2. Patients receiving Coroflex ISAR NEO stents.\n3. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthics Committee of the respective clinical site.\n\nExclusion Criteria:\n\n1. Patients with a mixture of other DESs\n2. Terminal illness with life expectancy \\\u003C1 year.\n3. Patients with cardiogenic shock",{"count":289,"type":21},1000,"The objective of this study is to evaluate the effectiveness and safety of Coroflex ISAR NEO stents in comparison to other drug-eluting stents (DES) in real-world practice.",[292,27],"Coronary Artery Stenosis",[294],"percutaneous coronary intervention",{"date":296,"type":40},"2026-06-25",{"date":298,"type":40},"2025-01-09",{"date":178,"type":21},{"name":157,"class":47},{"id":302,"slug":4,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":11,"sex":17,"minAge":308,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":22,"phases":311,"briefSummary":312,"conditions":313,"keywords":315,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":317,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":323},"100503025","NCT05829889","Fractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease","A Comparison of Fractional Flow Reserve- Versus Angiography-Guided Percutaneous Coronary Intervention in Patients With Left Main Coronary Artery Disease","FATE-MAIN","Inclusion Criteria:\n\n1. The subject must be ≥20 years of age with angina and\u002For evidence of myocardial ischemia.\n2. Significant de novo LMCA disease, defined as ≥ 50% diameter stenosis by visual estimation with or without concomitant non-left main major epicardial coronary artery disease, amenable to PCI with drug-eluting stent(DES) implantation.\n3. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthical Committee of the respective clinical site.\n\nExclusion Criteria:\n\n1. left anterior descending coronary artery (LAD) or left circumflex coronary artery (LCx) chronic total occlusion (CTO)\n2. Extremely calcified or tortuous vessels precluding FFR measurement.\n3. The presence of complex coronary disease anatomy or lesion characteristics or other cardiac condition(s) which leads the participating interventional cardiologist to believe that PCI is not suitable (i.e. the subject should be managed with coronary artery bypass graft or medical therapy alone).\n4. Recent ST Elevation Myocardial Infarction(\\\u003C7 days prior to randomization).\n5. Cardiogenic shock and\u002For need for mechanical\u002Fpharmacologic hemodynamic support.\n6. Severe left ventricular dysfunction (ejection fraction \\\u003C30%).\n7. Requirement for other cardiac surgical procedure (e.g., valve replacement or aorta surgery).\n8. Contraindication or inability to take aspirin or P2Y12 inhibitors (clopidogrel, ticagrelor, or clopidogrel).\n9. Prior PCI of the left main trunk.\n10. Prior coronary artery bypass graft surgery.\n11. Subjects requiring or who may require additional surgery (cardiac or noncardiac) within 1 year.\n12. End-stage renal disease requiring renal replacement therapy.\n13. Liver cirrhosis.\n14. Pregnant and\u002For lactating women.\n15. Concurrent medical condition with a limited life expectancy of less than 2 years.\n16. Subjects who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period. However, where at least one or more conditions are satisfied, it could be an exception according to an investigator's discretion;\n\n1\\) Participated in the observational study expected no effect on the safety and\u002For effectiveness evaluation of this trial.\n\n2\\) Screening failed before any interventional factor is involved.\n\n3\\) Participated in academic trials like strategic comparison studies conducted under standard therapy provided that there is no additional risk or a specific procedure to a subject and no interference between this trial and other studies.","20 Years",{"count":310,"type":21},960,[24],"The primary purpose of the study was to determine whether the 2-year probability of major adverse cardiac events (primary composite outcome) differed significantly between patients who underwent angiography-guided Percutaneous Coronary Intervention(PCI) and those who underwent Fractional Flow Reserve(FFR)-guided PCI in patients with Left Main Coronary Artery disease(LMCA).",[314,27],"Coronary Artery Disease Left Main",[316,195],"Fractional Flow Reserve",{"date":173,"type":40},{"date":319,"type":40},"2024-04-25",{"date":321,"type":21},"2027-12",{"name":157,"class":47},49,{"id":325,"slug":4,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":17,"minAge":140,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":332,"conditions":333,"keywords":334,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":346},"100501329","NCT05807841","Clinical Impact of Intravascular Ultrasound-Based Artificial Intelligence Technologies (INNOVATE-PCI)","Influence of Novel Intravascular Ultrasound-Based Artificial Intelligence Technologies on Event Reduction Following Percutaneous Coronary Intervention (INNOVATE-PCI)","Inclusion Criteria:\n\n* Age 19 years or older\n* Symptomatic angina patients with objective myocardial ischemia\n* Patients with at least one major epicardial coronary artery that requires stent implantation\n* Subject who signs with informed consent form\n\nPatient exclusion Criteria:\n\n* ST-segment elevation MI at admission\n* Patients who underwent coronary artery bypass surgery or heart transplantation\n* Left ventricular ejection fraction \\\u003C30%\n* Cardiogenic shock\n* Patients whose life expectancy \\\u003C2 years\n* Woman who are breastfeeding, pregnant or planning to become pregnant during study\n* Patients in whom anti-platelets or heparin is contraindicated\n\nLesion exclusion Criteria:\n\n* Left main culprit lesion (angiographic diameter stenosis \\>50%)\n* Thrombus-containing lesion\n* In-stent restenosis\n* Side branch lesion\n* Chronic total occlusion\n* Small vessel with reference diameter \\\u003C2.5mm\n* Coronary spasm despite administration of nitrate\n* Inability for imaging catheter to pass through tight stenosis, calcification, angulations\n* Poor image quality\n* Angiographically visible collateral vessels",{"count":331,"type":21},3000,"This study is a prospective, multicenter study in the real practice to validate the diagnostic performances and clinical impact of coronary angiography \\& intravascular ultrasound (IVUS)-based models developed by machine learning (ML).",[27],[294,335,336,337,338],"artificial intelligence","machine learning","intravascular ultrasound","coronary angiography",{"date":296,"type":40},{"date":341,"type":40},"2020-02-20",{"date":343,"type":21},"2029-12-31",{"name":345,"class":47},"Asan Medical Center",16,{"id":348,"slug":4,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":354,"conditions":355,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":362,"leadSponsor":364,"locationsCount":48},"100644344","NCT07662317","Construction of a Prospective Cohort Database for the Perioperative Period of Cardiac Surgery","Inclusion Criteria:\n\n* Patients undergoing cardiac surgery from May 1, 2026 to December 31, 2031\n\nExclusion Criteria:\n\n* Refusal to provide informed consent",{"count":353,"type":21},10000,"Cardiovascular disease (CVD) is the leading cause of global morbidity and mortality, with its prevalence increasing significantly from 1990 to 2019. Establishing a comprehensive cardiac surgery database is crucial for exploring perioperative prognostic factors and improving clinical outcomes.\n\nThis muti-center, prospective observational study aims to construct a prospective cohort database for perioperative cardiac surgery. We plan to enroll adult patients who undergo cardiac surgery with cardiopulmonary bypass at the Second Affiliated Hospital of Zhejiang University and other hospitals from May 1, 2026 to December 31, 2031. Multi-dimensional perioperative data, including laboratory tests, hemodynamics, intraoperative echocardiography, and perioperative medications, will be collected and integrated, along with epidemiological data, clinical diagnosis and treatment information, multimodal data, and follow-up outcomes. An interconnected big data sharing platform will also be built.\n\nThis database will provide a valuable resource for multi-level researches such as perioperative risk assessment, individualized prevention, precise diagnosis and treatment, and therapeutic efficacy monitoring. It will also help optimize surgical and perioperative management, improve the quality of cardiac surgery, and provide evidence for the refinement of China's healthcare system, ultimately enhancing perioperative safety and rehabilitation efficiency of patients.",[356,27,357,358],"Valve Heart Disease","Coronary Heart Disease","Aortic Diseases","2026-06-22",{"date":228,"type":40},{"date":296,"type":21},{"date":363,"type":21},"2032-05-31",{"name":365,"class":47},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":367,"slug":4,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":22,"phases":375,"briefSummary":376,"conditions":377,"keywords":378,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":380,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":386},"100607602","NCT07190690","Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions","Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions (DestinACSion Study)","DestinACSion","Inclusion Criteria:\n\nPatients who meet ALL inclusion criteria will be included:\n\n* Patients aged ≥18 years, and\n* Patients diagnosed with an acute coronary syndrome (ACS), either SCASEST (Acute Coronary Syndrome without Persistent ST-Segment Elevation) or IAMCEST (Acute Myocardial Infarction with Persistent ST-Segment Elevation), for which they will undergo PCI, and\n* Patients with de novo lesions in vessels with a reference diameter of ≥2.25 mm and ≤4.5 mm in whom implantation of one or more DES is clinically indicated, and\n* Patients who have been informed of the characteristics of the study and have provided written informed consent.\n\nExclusion Criteria:\n\nPatients must not meet any of the following exclusion criteria:\n\n* Patients in cardiogenic shock according to the severity criteria defined by the Society of Cardiovascular Angiography and Interventions (SCAI): \"C\" (Classic Shock), \"D\" (Deteriorating) and \"E\" (Extremis).\n* Patients unable to provide informed consent.\n* Patients with a known hypersensitivity or allergy to aspirin or any P2Y12 receptor inhibitor (clopidogrel, prasugrel, ticagrelor), heparin, contrast agents, or any of the components of DES.\n* Patients with active bleeding at the time of PCI requiring medical attention.\n* Patients with planned surgery within the next 3 months.\n* Patients with any medical condition that limits a life expectancy of less than 12 months.\n* Patients participating in another clinical trial in which the primary endpoint was not met.\n* Pregnant or breastfeeding women of childbearing potential with a positive pregnancy test.",{"count":374,"type":21},2100,[24],"To evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention).\n\nTo compare the clinical safety and efficacy by comparing net clinical events (defined as the combination of ischemic and hemorrhagic events) of the two DES used at 12 months after PCI.",[27],[379],"Drug Eluting Stents",{"date":228,"type":40},{"date":382,"type":40},"2025-12-19",{"date":384,"type":21},"2030-10-15",{"name":280,"class":47},17,{"id":388,"slug":4,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":11,"sex":17,"minAge":140,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":22,"phases":396,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":403,"locationsCount":404},"100471413","NCT05418556","Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent","Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug","OPTIMIZE-APT","Inclusion Criteria:\n\n1. Men or women ≥19 years\n2. Typical chest pain or objective evidence of myocardial ischemia suitable for PCI\n3. Significant de novo coronary artery lesions suitable for DES implantation\n4. Patients who underwent optimized stent implantation either by IVUS or OCT\n\n   * Using IVUS\n\n     * MSA \\>5.5 mm2, or MSA \\>90% of the MLA at the distal reference segment\n     * Plaque burden \\\u003C50% with 5 mm of both stent edge\n     * No edge dissection, thrombus or plaque protrusion\u002Fstent area \\\u003C10%\n   * Using OCT\n\n     * MSA \\>4.5 mm2, or MSA \\>90% of the MLA at the distal reference segment\n     * No significant malapposition\n     * No significant edge dissection, thrombus or plaque protrusion\u002Fstent area \\\u003C10%\n5. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthical Committee of the respective clinical site\n\nExclusion Criteria:\n\n1. Angiographic exclusion criteria: any of the followings 1. Bypass graft lesions 2. Lesions in which impaired delivery of imaging catheters is expected:\n\n   * Extreme angulation (≥90°) proximal to or within the target lesion.\n   * Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion.\n   * Heavy calcification proximal to or within the target lesion.\n2. In-stent restenosis\n3. Hypersensitivity or contraindication to device material and its degradants and cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be adequately pre-medicated.\n4. Persistent thrombocytopenia (platelet count \\\u003C80,000\u002Fl)\n5. Any history of hemorrhagic stroke or intracranial hemorrhage \u002F TIA or ischemic stroke within the past 6 months\n6. A known intolerance or hypersensitivity to a study drug (aspirin, clopidogrel or ticagrelor) or heparin\n7. Patients requiring long-term oral anticoagulants or cilostazol\n8. Any surgery requiring general anesthesia or discontinuation of aspirin and\u002For an ADP antagonist is planned within 12 months after the procedure.\n9. A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer.\n10. Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.\n11. History of liver cirrhosis (Child-Pugh B or C) or biliary tract obstruction\n12. Life expectancy \\\u003C 1 years for any non-cardiac or cardiac causes\n13. Cardiogenic shock at the index admission\n14. Patient's pregnant or breast-feeding\n15. Active bleeding or extreme-risk for major bleeding (e.g. active peptic ulcer disease, gastrointestinal pathology with a high risk for bleeding, malignancies with a high risk for bleeding)\n16. Unwillingness or inability to comply with the procedures described in this protocol.",{"count":395,"type":21},3944,[192],"Objectives: To assess the safety of tailored antiplatelet therapy (short DAPT followed by P2Y12 inhibitor alone strategy) in patients who received optimized DES implantation guided by intravascular imaging (IVUS or OCT)\n\nHypothesis: Tailored antiplatelet strategy (short DAPT followed by P2Y12 inhibitor alone) is superior to conventional antiplatelet strategy in terms of clinically relevant bleeding and noninferior for ischemic composite adverse events in patients who received intravascular imaging-guided optimized DES implantation. (Optimized stent evaluated by on-site IVUS\u002FOCT could act as an essential criterion for decision making for tailored antithrombotic strategy)",[27],{"date":296,"type":40},{"date":401,"type":40},"2022-10-21",{"date":178,"type":21},{"name":345,"class":47},33,{"id":406,"slug":4,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":412,"targetDuration":414,"studyType":143,"phases":4,"briefSummary":415,"conditions":416,"keywords":418,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":428},"100623620","NCT07399002","LONG NAGOMI™ PMCF STUDY","Long Coronary Lesions: Safety and Performance of the Ultimaster Nagomi™ Stent in This Setting With a One-to-one Approach -One Lesion, One Stent- LONG NAGOMI™ PMCF STUDY","LONG NAGOMI","Inclusion Criteria:\n\n* Patients who meet ALL inclusion criteria will be included:\n* Patients aged ≥ 18 years AND;\n* Patients who according to standard practice of the hospital are amenable to PCI as indicated and considered adequate according to the European clinical practice guidelines on coronary revascularization AND;\n* Patients with at least one lesion fulfilling the \"long lesion criteria\" suitable for a single stent approach AND;\n* Patients who have been informed of the characteristics of the study and have provided written informed consent AND;\n* Intention to treat all lesions with the Ultimaster Nagomi™ stent\n\nExclusion Criteria:\n\n* Patients must not meet any of the following exclusion criteria:\n* Patients who expressly decline to participate in the study.\n* Pregnant or breastfeeding women.\n* Patients with acute coronary syndrome (ACS) under conditions of cardiogenic shock (Killip class 4).\n* Patients with contraindications or hypersensitivity to sirolimus.\n* Patients with a life expectancy of less than 2 years.\n* Patients in whom any surgery requiring general anesthesia is planned, comorbidity or indication likely necessitating the discontinuation of dual anti-platelet therapy before the recommended duration of dual anti-platelet therapy per the ESC or national guidelines.\n* Patients included in other clinical trials that did not reach the primary objective.",{"count":413,"type":21},1039,"12 Months","The study is designed as a prospective, multi-center, observational PMCF (post-market clinical follow-up) study of the Ultimaster Nagomi™ \\_stent (lengths of 38, 44 and 50 mm) in the treatment of coronary artery disease according to the indications approved in the CE marking.",[27,417],"Ischemic Heart Disease",[419,420],"MDR (Medical Device Regulations)","PMCF (Post-Market Clinical Follow-up)","2026-06-19",{"date":228,"type":40},{"date":424,"type":40},"2026-02-27",{"date":426,"type":21},"2029-01-01",{"name":280,"class":47},7,{"id":430,"slug":4,"hasResults":11,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":434,"eligibilityCriteria":435,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":436,"targetDuration":438,"studyType":143,"phases":4,"briefSummary":439,"conditions":440,"keywords":445,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":48},"100640402","NCT07614386","Radial Access Data in Vascular Interventions Registry","Radial Access Data in Vascular Interventions: A Prospective Observational Registry Study","RADIUS","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients undergoing routine percutaneous vascular interventions via radial or ulnar artery access\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Procedures performed without radial or ulnar artery access\n* Incomplete procedural or clinical data\n* Refusal to participate in the registry",{"count":437,"type":21},20000,"1 Year","The RADIUS study is a prospective observational registry designed to collect real-world data regarding radial and ulnar artery access in percutaneous vascular interventions. The study aims to evaluate procedural characteristics, access-site complications, procedural success, and short-term clinical outcomes associated with transradial and transulnar vascular access.\n\nPatients undergoing routine percutaneous vascular interventions via radial or ulnar artery access at Mersin Medical Park Hospital will be consecutively enrolled. Demographic, clinical, angiographic, procedural, and post-procedural data will be prospectively collected and analyzed.\n\nThe study was initially designed as a single-center registry; however, following Institutional Review Board (IRB) approval, expansion into a multicenter registry with participating centers is planned.\n\nThis study is observational in nature and does not involve any experimental treatment, device, or intervention beyond standard clinical care.",[441,442,443,27,444],"Radial Artery Occlusion","Radial Artery Spasm","Vascular Access Complications","Peripheral Arterial Disease",[446,447,448,449,35,450,451,442,452],"Radial access","Ulnar access","Transradial intervention","Coronary angiography","Vascular complications","Radial artery occlusion","Registry","2026-06-18",{"date":228,"type":40},{"date":456,"type":40},"2026-05-15",{"date":458,"type":21},"2031-05-20",{"name":460,"class":47},"Mersin Medicalpark Hastanesi",{"id":462,"slug":4,"hasResults":11,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":466,"eligibilityCriteria":467,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":468,"targetDuration":266,"studyType":143,"phases":4,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":48},"100641396","NCT07659119","Assessment of CT-FFR in Patients With CCS: A Prospective Multicenter Cohort Study","Assessment of Coronary Computed Tomography-Derived Fractional Flow Reserve in Patients With Chronic Coronary Syndrome: A Prospective Multicenter Cohort Study","ACCURATE-PRO","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Clinical diagnosis of chronic coronary syndrome (CCS).\n* Completed coronary computed tomography angiography (CCTA) examination and successfully obtained CT-derived fractional flow reserve (CT-FFR) results.\n* The subject or their legal representative voluntarily participates in this study and has signed the written informed consent form.\n\nExclusion Criteria:\n\n* Acute coronary syndrome (ACS), including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), or acute episodes of unstable angina.\n* Unable to obtain valid CT-FFR results, or the image quality is insufficient to support analysis.\n* Pregnant patients or those who intend to become pregnant during the study period.\n* Non-cardiac comorbidities indicating a life expectancy of less than one year.\n* Failure to sign the informed consent form.\n* Inability to complete the follow-up or explicit refusal to participate in the follow-up.\n* Patients with cognitive impairment or psychiatric disorders confirmed by clinical diagnosis or investigator assessment.\n* Patients who are illiterate or semi-literate, or who, due to any visual impairment or reading\u002Fwriting disability, are unable to independently read the subject information sheet without assistance and are unable to personally provide written informed consent.\n* Any other conditions deemed unsuitable for participation in this study by the investigators",{"count":331,"type":21},"The ACCURATE-PRO study is an investigator-initiated, prospective, multicenter, observational, real-world cohort study. The core objective in managing chronic coronary syndrome (CCS) is to identify clinically significant myocardial ischemia to guide treatment decisions and improve long-term prognosis. While coronary computed tomography angiography (CCTA) is a crucial non-invasive anatomical imaging tool, it has limitations in determining the functional significance of coronary stenosis. Computed tomography-derived fractional flow reserve (CT-FFR) provides this functional assessment non-invasively based on CCTA images. However, there is a lack of systematic, prospective, multicenter evidence regarding its clinical value in risk stratification, treatment decision support, and prognostic evaluation for a continuous, real-world spectrum of CCS patients in China.\n\nThis study aims to evaluate the relationship between abnormal CT-FFR results and the risk of 1-year major adverse clinical events in CCS patients undergoing CCTA and CT-FFR. The study hypothesizes that abnormal CT-FFR is associated with a higher risk of 12-month major adverse clinical events, and that CT-FFR results are significantly correlated with subsequent treatment strategies, providing important value in risk stratification and mid-to-long-term prognosis.\n\nThe trial plans to consecutively enroll approximately 3,000 patients across multiple clinical centers in China. Eligible participants must be 18 years or older, have a clinical diagnosis of CCS, and have successfully obtained CT-FFR results following a CCTA examination. Patients will be excluded if they have acute coronary syndrome (such as STEMI, NSTEMI, or acute unstable angina), unanalyzable CT-FFR results\u002Fimage quality, or non-cardiac conditions limiting their life expectancy to less than one year.\n\nSince this is an observational study, it will not alter routine clinical care pathways or assign interventions. The primary exposure factor analyzed will be the lowest CT-FFR result per patient, comparing an abnormal CT-FFR group (≤ 0.80) to a normal CT-FFR group (\\> 0.80).\n\nParticipants will be followed up via telephone, outpatient visits, or hospitalization at 6, 12, 24, and 60 months after enrollment. The primary endpoint is a composite of all-cause death, myocardial infarction (MI), or ischemia-driven revascularization within 1 year after enrollment. Key secondary endpoints include the occurrence of the primary endpoint at 24 and 60 months, target vessel failure (a composite of cardiac death, target vessel MI, or target vessel revascularization), stroke, health economics analysis, and the association between CT plaque characteristics and clinical outcomes.",[27],"2026-06-16",{"date":359,"type":40},{"date":474,"type":40},"2024-05-01",{"date":476,"type":21},"2034-05-31",{"name":365,"class":47},{"id":479,"slug":4,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":485,"enrollmentInfo":486,"targetDuration":4,"studyType":22,"phases":488,"briefSummary":489,"conditions":490,"keywords":504,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":48},"100612800","NCT07258290","Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions","Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries","BIOMAG-III","Clinical Inclusion Criteria:\n\n1. Subject is ≥ 18 years and ≤ 80 years of age\n2. Subject has provided written informed consent as approved by the Ethics Committee \u002F Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures\n3. Subject is eligible for PCI according to the applicable guidelines\n4. Subject is an acceptable candidate for coronary artery bypass surgery\n5. Subjects with stable or unstable angina pectoris, documented silent ischemia\u002Fabnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion\n\n   Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:\n   * Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) \\[lesion(s) causing the acute STEMI\\];\n   * Subject is hemodynamically stable with documented declining cardiac biomarkers;\n   * Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)\n6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor or ticlopidine\n7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to randomization)\n8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study\n\nAngiographic Inclusion Criteria:\n\n1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries\n2. Target vessel must have a reference diameter between 2.5-4.2 mm by operator visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) \u002F Intravascular Ultrasound (IVUS) \u002F Optical Coherence Tomography (OCT)\n3. Target lesion(s) must be ≤ 36 mm in length by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT, (or \\\u003C 20 mm for target lesion(s) to be treated with a study device \\\u003C 3.0 mm in diameter) and must be amenable to treatment with a single study device\n4. Target lesion stenosis ≥ 50% and \\\u003C 100% by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT. Target lesion stenosis \\\u003C 70% by visual estimation, should have clinical justification for treatment as per local standards.\n5. Target lesion must have a Thrombolysis in Myocardial Infarction (TIMI) flow ≥ 1\n\nClinical Exclusion Criteria:\n\n1. Subject is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study\n2. Subject has clinical symptoms and\u002For electrocardiogram (ECG) changes consistent with STEMI \\\u003C 72 hours prior to the index procedure Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment\n3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \\\u003C 72 hours prior to the index procedure\n4. Subject is on dialysis or has impaired renal function (serum creatinine \\> 2.5 mg\u002FdL or 221 µmol\u002FL, determined within 7 days prior to the index procedure)\n5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus, everolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminum, tantalum), or Xience stent material (cobalt, chromium, tungsten, nickel, methacrylic polymer, and fluoropolymer)\n6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)\n7. Life expectancy less than 1 year\n8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained\n9. In the investigator's opinion subject will not be able to comply with the follow-up requirements\n10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e., triple therapy) can be maintained for a minimum of 1 month\n11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure\n12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT\n13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug\n14. Subject has known severe aortic or mitral valve stenosis\u002Finsufficiency or has previously undergone transcatheter aortic valve replacement (TAVR)\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion\n2. Left main coronary artery disease\n3. Target lesion is totally occluded (100% stenosis)\n4. Thrombus in target vessel\n5. Future planned staged PCI either in target or non-target vessel\n6. Ostial target lesion within the left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA) (within 5.0 mm of vessel origin)\n7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation\n8. Target lesion is located in or supplied by an arterial or venous bypass graft\n9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and\u002For cutting\u002Fscoring balloon as described in angiographic exclusion criteria 10\n10. Target lesion requires treatment with a device other than the non-compliant balloon and\u002For cutting\u002Fscoring balloon prior to scaffold\u002Fstent placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons, etc.)\n11. Target vessel was treated with brachytherapy any time prior to the index procedure.\n12. Unsuccessful pre-dilatation, defined as residual stenosis \\> 20% (by visual estimation) and\u002For angiographic complications (e.g., distal embolization, side branch closure, flow-limiting dissections)","80 Years",{"count":487,"type":21},1859,[24],"The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system",[491,492,493,494,495,496,497,498,499,500,501,27,502,196,503],"Coronary Disease","Heart Diseases","Cardiovascular Diseases","Arteriosclerosis","Arterial Occlusive Diseases","Vascular Diseases","Chest Pain","Pain","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Myocardial Ischemia","Angina Pectoris",[505,506,507,508],"Resorbable Magnesium Scaffold","Sirolimus","RMS","Drug eluting absorbable metal scaffold","2026-06-15",{"date":511,"type":40},"2026-06-17",{"date":513,"type":40},"2026-06-11",{"date":515,"type":21},"2033-06",{"name":517,"class":518},"Teleflex","INDUSTRY",{"id":520,"slug":4,"hasResults":11,"nctId":521,"briefTitle":522,"officialTitle":522,"acronym":523,"eligibilityCriteria":524,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":22,"phases":527,"briefSummary":528,"conditions":529,"keywords":530,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":541},"100566642","NCT06657833","DEBSCAN-IVL. Drug Eluting Balloon or Drug Eluting Stent to Treat CAlcified Nodules After IntraVascular Lithotripsy.","DEBSCAN-IVL","Inclusion Criteria:\n\nPatients must meet all inclusion criteria:\n\n* Patients \\>18 years admitted for stable coronary artery disease or acute coronary syndromes and indication for percutaneous coronary intervention (PCI) and\n* Severe coronary lesion with calcified nodule, confirmed with intracoronary imaging (optical coherence tomography or intravascular ultrasound) and;\n* Lesion to treat in a vessel between 2.5 and 4 mm.\n\nExclusion Criteria:\n\nPatients must not meet any criteria\n\n* Inability to provide oral and written informed consent or unwillingness to come back for systematic angiographic follow-up.\n* Pregnant or breastfeeding patients.\n* Cardiogenic Shock or Cardiac arrest at the moment of the index procedure.\n* Impossibility to maintain double antiplatelet treatment during at least 1 month.\n* Life expectancy \\\u003C1 year.\n* Index lesion at left main stem.\n* Aorto-ostial lesion.\n* Target lesion previously treated with stents or DEB.\n* High thrombus burden in the target lesion (TIMI thrombus scale≥3).",{"count":526,"type":21},128,[24],"International, investigator-driven, multicenter, open-label, prospective randomized controlled trial where patients with de novo lesions due to calcified nodules (CN) were randomized to drug eluting balloon (DEB) or drug eluting stents (DES).",[27],[531,532,533,534],"Calcified Nodules","Calcified lesions","Drug eluting balloon","Drug eluting stent",{"date":471,"type":40},{"date":537,"type":40},"2024-12-17",{"date":539,"type":21},"2027-10-30",{"name":280,"class":47},13,{"id":543,"slug":4,"hasResults":11,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":547,"eligibilityCriteria":548,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":549,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":551,"conditions":552,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":568,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":575},"100172884","NCT01524276","Product Surveillance Registry","Medtronic Product Surveillance Registry","PSR","Inclusion Criteria:\n\n* Patient or legally authorized representative provides written authorization and\u002For consent per institution and geographical requirements\n* Patient has or is intended to receive or be treated with an eligible Medtronic product\n* Patient within enrollment window relative to therapy initiation or meets criteria for retrospective enrollment\n\nExclusion Criteria:\n\n* Patient who is, or will be, inaccessible for follow-up\n* Patient with exclusion criteria required by local law\n* Patient is currently enrolled in or plans to enroll in any concurrent drug and\u002For device study that may confound results",{"count":550,"type":21},100000,"The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.",[553,554,555,556,557,558,559,560,561,562,563,564,565,566,27,567],"Cardiac Rhythm Disorders","Urological Disorders","Neurological Disorders","Cardiovascular Disorders","Digestive Disorders","Intracranial Aneurysm","Mechanical Circulatory Support","Respiratory Therapy","Aortic, Peripheral Vascular and Venous Disorders","Minimally Invasive Surgical Procedures","Diagnostic Techniques and Procedures","Surgical Procedures, Operative","Renal Insufficiency","Neurovascular","Ear, Nose and Throat Disorder",{"date":511,"type":40},{"date":570,"type":4},"2012-01",{"date":572,"type":21},"2040-01",{"name":574,"class":518},"Medtronic",395,{"id":577,"slug":4,"hasResults":11,"nctId":578,"briefTitle":579,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":582,"targetDuration":414,"studyType":143,"phases":4,"briefSummary":584,"conditions":585,"keywords":586,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":598},"100582426","NCT06863155","Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation","ACO_FLEX","Inclusion Criteria:\n\nPatients must meet all inclusion criteria:\n\n* Patients with Signed informed consent and\n* Patients with \\>=18 years old and\n* Patients with chronically receiving oral anticoagulation treatment with any type of anticoagulant for any reason and\n* Patients with de novo Coronary artery disease requiring both elective or urgent percutaneous revascularization due to stable coronary artery disease or acute coronary syndrome with or without ST-segment elevation, and in which an ultrathin strut Sirolimus-eluting stent with bioabsorbable polymer has been used\n\nExclusion Criteria:\n\nPatients do not have to meet any exclusion criteria\n\n* Patients treated percutaneously with any type of stent other than the SupraFlex Cruz® in the 6 months prior to the index procedure in which he or she is included.\n* Use in the same procedure or in a scheduled procedure of other stents different from the one evaluated for the treatment of another vessel(s).\n* Patients treatment for restenosis or stent thrombosis.\n* Patients presentation in cardiogenic shock or after cardiorespiratory arrest.\n* Patients with allergy to any of the components of the stent to be used.\n* Patients with impossibility for follow-up.\n* Patients with life expectancy less than 1 year.",{"count":583,"type":21},500,"Patients receiving chronic oral anticoagulation with indication for percutaneous coronary revascularization with stent implantation, and needing for antiplatelet therapy, are at high risk of bleeding. The new generation of ultrathin strut sirolimus-eluting stent with bioabsorbable polymer allow for shorter antiplatelets regimens and could be a good option for this high-bleeding risk patients.",[27,417],[587,588,589,590,195],"Chronic oral anticoagulation","Ultrathin-strut stent","Biodegradable polymer","High-bleeding risk","2026-06-14",{"date":471,"type":40},{"date":594,"type":40},"2025-05-06",{"date":596,"type":21},"2029-03-31",{"name":280,"class":47},12,{"id":600,"slug":4,"hasResults":11,"nctId":601,"briefTitle":602,"officialTitle":602,"acronym":4,"eligibilityCriteria":603,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":604,"targetDuration":266,"studyType":143,"phases":4,"briefSummary":606,"conditions":607,"keywords":608,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":257},"100635993","NCT07559903","ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety)","Inclusion Criteria:\n\n* All adult patients (≥ 18 years of age) undergoing PCI for de novo CAD using DCB\n\nExclusion Criteria:\n\n* Patients under the age of 18; PCI procedures without the utilization of DCB; PCI procedures for non de novo lesions",{"count":605,"type":21},5000,"The primary objective of this protocol is to develop a comprehensive, multicenter international prospective registry to capture long-term clinical outcomes for adult patients undergoing percutaneous coronary intervention (PCI) with drug-coated balloons (DCB) for de novo coronary artery disease.",[27],[609,35,610],"Drug coated balloon","Target lesion failure","2026-06-12",{"date":509,"type":40},{"date":614,"type":21},"2026-06",{"date":616,"type":21},"2031-05",{"name":618,"class":47},"Emory University",{"id":620,"slug":4,"hasResults":11,"nctId":621,"briefTitle":622,"officialTitle":623,"acronym":4,"eligibilityCriteria":624,"healthyVolunteers":11,"sex":17,"minAge":625,"maxAge":485,"enrollmentInfo":626,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":628,"conditions":629,"keywords":631,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":637,"completionDateStruct":638,"leadSponsor":640,"locationsCount":48},"100642455","NCT07650487","Perioperative Myocardial Injury in Patients Undergoing Coronary Artery Bypass Grafting: A Prospective Clinical Study","Prospective Clinical Study for Evaluation of Perioperative Myocardial Injury Using High-Sensitivity Troponin and Cardiac MRI in Patients Undergoing Coronary Artery Bypass Grafting (CABG)","Inclusion Criteria:\n\n1. Age ≥ 21 years\n2. Undergoing CABG for unstable angina\n3. Able to provide written informed consent\n4. No major cardiovascular event in the prior 6 months\n\nExclusion Criteria:\n\n1. Significant hepatic, renal, or other major organ dysfunction\n2. Pregnancy or breastfeeding\n3. Withdrawal during the study\n4. Contraindication to cardiac MRI (metal implants, claustrophobia, etc.)","21 Years",{"count":627,"type":21},150,"Perioperative myocardial injury (PMI) following coronary artery bypass grafting (CABG) is associated with postoperative morbidity, mortality, and long-term outcomes. High-sensitivity troponin assays and cardiac MRI offer reliable diagnostic tools for PMI, but evidence regarding optimal diagnostic thresholds and perioperative imaging strategy is limited. This prospective clinical study aims to determine the incidence of perioperative myocardial injury using multimodal assessments including high-sensitivity troponin, electrocardiogram, echocardiography, cardiac MRI, and perioperative cardiovascular events.",[630,27],"Myocardial Injury",[632,92,633,634,27],"Perioperative Myocardial Injury","Cardiac MRI","hs-Troponin","2026-06-10",{"date":471,"type":40},{"date":126,"type":21},{"date":639,"type":21},"2027-07-30",{"name":641,"class":47},"Second Hospital of Jilin University",""]